Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY.
马萨诸塞州沃特敦-（商业资讯）-2024年5月29日-Enanta制药有限公司。（NASDAQ: ENTA）是一家临床阶段的生物技术公司，致力于创造用于病毒学和免疫学指示的小分子药物。今天日，该公司宣布Jay R. Luly博士，总裁兼首席执行官和Tara L. Kieffer博士，首席产品战略官将于2024年6月5日美国东部标准时间上午7:30在纽约的杰富瑞环球卫生保健大会上举行炉边聊天。
A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days.
本次活动的现场网络直播可访问Enanta网站“投资者”页面下的“活动和演示文稿”部分。www.enanta.com。演示文稿的重播将在演示结束后提供，并将存档至少30天。
About Enanta Pharmaceuticals, Inc.
关于Enanta制药公司
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta's research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection.
Enanta使用其强大的化学驱动方法和药物发现能力，致力于成为病毒学和免疫学指示的小分子药物发现和开发领域的领导者。Enanta的研发项目目前集中于呼吸道合胞病毒(RSV)和慢性自发性荨麻疹(CSU)，并且该公司以前已将临床阶段的化合物推广至严重急性呼吸综合症冠状病毒2型（COVID-19）和慢性乙型肝炎病毒（HBV）感染。Enanta发现的一种蛋白酶抑制剂Glecaprevir是治疗慢性丙型肝炎病毒感染的疗法之一，Abbvie以MAVYRET(U.S.)和MAVIRET(ex-U.S.)(glecaprevir/pibrentasvir)为贸易名称在许多国家销售。Enanta从与AbbVie合作开发的丙型肝炎病毒产品中的一部分专利权可提供持续的资金支持给Enanta的运营。请访问http://www.enanta.com
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus infection (HCV) and is sold by AbbVie in numerous countries under the trade names MAVYRET(U.S.) and MAVIRET(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit http://www.enanta.com for more information.
https://www.businesswire.com/news/home/20240529474424/en/关于Calix
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529474424/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240529474424/en/
Media and Investors:
Jennifer Viera
jviera@enanta.com
媒体和投资者：Jennifer Viera
jviera@enanta.com
资料来源：Enanta制药公司。
Source: Enanta Pharmaceuticals, Inc.